Given the uncertainty around its revenue growth, we advise short-term investors to remain cautious when investing in MRNA ...

Various respiratory illnesses as well as the Norovirus, otherwise known as the stomach flu, are circulating in the Chippewa Valley. “We’ve seen an increase in COVID-19, RSV, influenza, as well as ...

Learn how analytical methodologies can be used to identify RSV pre- and post-fusion proteins for vaccine development.

MRNA's competitive landscape, particularly against Pfizer, and higher forward P/S ratio suggest the stock is overvalued and ...

Revenue for Arexvy and Abrysvo fell sharply year over year in the fourth quarter due to narrower U.S. guidelines for their ...

State health officials are seeing the highest numbers all winter lately with approximately 9.5 of the 600 tests for RSV ...

Broad-Spectrum Antiviral NV-387 Phase II Clinical Trial Responding to MPox Pandemic in Africa, Readying to Tackle Bird Flu ...

Moderna MRNA incurred a loss of $2.50 per share in the fourth quarter of 2024, narrower than the Zacks Consensus Estimate of ...

after vaccination. Arexvy was initially approved on May 3, 2023, for prevention of LRTD associated with RSV in adults aged 60 years or more, and has since been approved for the same indication in ...

Nasal vaccine devices have the potential to offer more convenient and more effective protection against a variety of viruses.

23, 2024 — A year after becoming available, vaccines to protect against RSV in newborns and older ... 2024 — Despite national medical guidelines supporting the use of antiviral medications ...